Rebecca Frey, PharmD
Rebecca Frey is a seasoned CEO and board director with twenty-five years of experience across small and large biopharma companies, including as CEO and COO in biotech startups. She currently serves as the CEO of Yarrow Biotechnology and as a Venture Partner with RTW Investments.
Prior to joining RTW she served as President and CEO of Siduma Therapeutics, a Yale spinout focused on heterobifunctional platforms. She has previously held key operational leadership roles in emerging biotech companies including EvolveImmune Therapeutics, Cardurion Pharmaceuticals and Prevail Therapeutics. Prior to these roles, she spent eleven years working in medical affairs, development, corporate affairs and manufacturing at Alexion Pharmaceuticals. At Alexion, Rebecca spearheaded the development of Solirisâ in new indications which have become multibillion dollar franchises and contributed to approvals of multiple new rare disease products. Earlier in her career she worked in development and medical affairs at Novartis Pharmaceuticals and was an Assistant Professor at Northeastern University.
In addition to her operating roles, Rebecca is an experienced biotech board member who also serves on the boards of Halda Therapeutics, Octant and Artelis Biopharma. She is directorship certified by the National Association of Corporate Directors. Rebecca was recently honored as a Vanguard in the BLOC 100 list of the most impactful women of color & allies shaping the future of healthcare, life Sciences, & biopharma.
Rebecca earned a Doctorate in Pharmacy from Northeastern University and completed her post-doctoral clinical research fellowship at Tufts Medical Center in the field of organ transplant therapeutics. She additionally holds an Executive Certificate in Management and Leadership from the MIT Sloan School of Management.
